More

    Europe Markets

    Myalepta | European Medicines Agency (EMA)

    OverviewMyalepta is a medicine used in addition to diet to treat lipodystrophy, where patients have loss of fatty tissue under the skin and...

    Karvezide | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Karvezide. It explains how the Committee for Medicinal Products for Human...

    CoAprovel | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for CoAprovel. It explains how the Committee for Medicinal Products for Human...

    Pluvicto | European Medicines Agency (EMA)

    OverviewPluvicto is a medicine used to treat cancer of the prostate (a gland of the male reproductive system). It is used when the...

    Elucirem | European Medicines Agency (EMA)

    OverviewElucirem is a ‘contrast agent’, a medicine used to improve the contrast of images obtained during magnetic resonance imaging (MRI) examinations. This helps...

    Vueway | European Medicines Agency (EMA)

    OverviewVueway is a ‘contrast agent’, a medicine used to improve the contrast of images obtained during magnetic resonance imaging (MRI) examinations. This helps...

    Repaglinide Krka | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP)...

    EMA establishes regular procedure for scientific advice on certain high-risk medical devices

    EMA, in close collaboration with the European Commission, has established a standard procedure for manufacturers of certain high-risk medical devices to request scientific...

    Kisqali | European Medicines Agency (EMA)

    OverviewKisqali is a medicine used to treat early breast cancer at high risk of coming back and breast cancer that is locally advanced...

    Remicade | European Medicines Agency (EMA)

    OverviewRemicade is an anti‑inflammatory medicine. It is usually used when other medicines or treatments have failed, in adults with the following diseases:rheumatoid arthritis...

    Nivestim | European Medicines Agency (EMA)

    OverviewNivestim is a medicine that stimulates the production of white blood cells and is used:to reduce the duration of neutropenia (low levels of...

    Urorec | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP)...

    Ilaris | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Ilaris. It explains how the Agency assessed the medicine to recommend...

    Ponvory | European Medicines Agency (EMA)

    OverviewPonvory is a medicine for treating adults with relapsing active forms of multiple sclerosis. Multiple sclerosis is a disease of the brain and spinal...

    Enyglid | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Enyglid. It explains how the Committee for Medicinal Products for Human...

    Wyost | European Medicines Agency (EMA)

    OverviewWyost is a medicine used to prevent bone complications in adults with advanced cancer that has spread to the bone. These complications include...